policy Archives

First Opinion By Stephen Asiimwe, Edith Nakku-Joloba and Aggrey Semeere

Isolated in Uganda: How Covid-19 evacuations highlight unfairness of global health partnerships

Exclusive By Rachel Cohrs

How Nancy Pelosi almost killed drug pricing reform — a gamble that expanded Democrats’ final deal

Politics By Lev Facher

Here’s how Biden can address high drug prices, without help from Congress

First Opinion By Natalie Ma

My company is developing new antibiotics. My resistant infection showed me we need them now

Politics By Rachel Cohrs

Democrats want to let Medicare negotiate drug prices. Has pharma found a way to lessen the blow, already?

Politics By Rachel Cohrs and Lev Facher

In a new policy proposal, Biden presses Congress to let Medicare negotiate drug prices

Politics By Rachel Cohrs

Vulnerable Senate Democrats escalate a push for Medicare to negotiate drug prices

Health By Lev Facher

For the first time ever, Lander’s White House science office will have an entire wing dedicated to health

D.C. Diagnosis By Nicholas Florko

Are pharma mergers bad for biotech?

Politics By Rachel Cohrs

Washington’s antitrust push could limit Amazon, Google’s health care ambitions

Biotech By Damian Garde and Nicholas Florko

Calls grow for an investigation into FDA approval of Biogen’s Alzheimer’s drug

First Opinion By Sevahn Vorperian and Stephen Quake

The PASTEUR Act can help win the war against superbugs

Politics By Nicholas Florko

Powerful Democrat’s new drug pricing manifesto hints at a carveout for small biotechs

D.C. Diagnosis By Rachel Cohrs

The lonely quest to create a commission to investigate Covid-19

Politics By Rachel Cohrs

Biogen isn’t the only drug company that will profit from the new Alzheimer’s drug Aduhelm

Politics By Nicholas Florko

BIO’s chief on the FDA commissioner rumors, drug pricing, and IP rights

Politics By Rachel Cohrs

Buying the data: Health care lobbyists fund their own policy analyses, clouding Washington debates

Business By Andrew Joseph

Member of FDA’s expert panel resigns over controversial Alzheimer’s therapy approval

First Opinion By David Blumenthal

Restore a better balance to public-private funding of biomedical research

Politics By Megan Molteni

California could become first state to mandate biosecurity screening by mail-order DNA companies

First Opinion By Parsa Erfani, Lawrence O. Gostin and Vanessa Kerry

Beyond a symbolic gesture: What’s needed to turn the IP waiver into Covid-19 vaccines

First Opinion By Jonathan Doh

Make drug companies partners — not adversaries — to expand global Covid-19 vaccine access

Opinions+ By John Freedman

The many benefits of expanding the reach of state all-payer claims databases

Health Tech By Andrew Joseph

Former Google CEO Schmidt says AI ‘will have its biggest impact’ in health care

Hospitals By Rachel Cohrs

Most Read

Biden abandons his push to lower drug prices

Key Senate committee considers a carveout for small biotech companies in drug pricing reforms

Senate Democrats eye drug pricing policies to fund $3.5 trillion budget deal

Tax exemptions for nonprofit hospitals: It’s time taxpayers get their money’s worth

The Trump administration quietly spent billions in hospital funds on Operation Warp Speed

9 ways Covid-19 may forever upend the U.S. health care industry

‘A number of new stars’: The definitive guide to the Trump administration’s coronavirus response team

‘We owe much to the Sackler family’: How gifts to a top medical school advanced the interests of Purdue Pharma

All Coverage

Isolated in Uganda: How Covid-19 evacuations highlight unfairness of global health partnerships

How Nancy Pelosi almost killed drug pricing reform — a gamble that expanded Democrats’ final deal

Here’s how Biden can address high drug prices, without help from Congress

My company is developing new antibiotics. My resistant infection showed me we need them now

Democrats want to let Medicare negotiate drug prices. Has pharma found a way to lessen the blow, already?

In a new policy proposal, Biden presses Congress to let Medicare negotiate drug prices

Vulnerable Senate Democrats escalate a push for Medicare to negotiate drug prices

For the first time ever, Lander’s White House science office will have an entire wing dedicated to health

Are pharma mergers bad for biotech?

Washington’s antitrust push could limit Amazon, Google’s health care ambitions

Calls grow for an investigation into FDA approval of Biogen’s Alzheimer’s drug

The PASTEUR Act can help win the war against superbugs

Powerful Democrat’s new drug pricing manifesto hints at a carveout for small biotechs

The lonely quest to create a commission to investigate Covid-19

Biogen isn’t the only drug company that will profit from the new Alzheimer’s drug Aduhelm

BIO’s chief on the FDA commissioner rumors, drug pricing, and IP rights

Buying the data: Health care lobbyists fund their own policy analyses, clouding Washington debates

Member of FDA’s expert panel resigns over controversial Alzheimer’s therapy approval

Restore a better balance to public-private funding of biomedical research

California could become first state to mandate biosecurity screening by mail-order DNA companies

Beyond a symbolic gesture: What’s needed to turn the IP waiver into Covid-19 vaccines

Make drug companies partners — not adversaries — to expand global Covid-19 vaccine access

The many benefits of expanding the reach of state all-payer claims databases

Former Google CEO Schmidt says AI ‘will have its biggest impact’ in health care

HHS plans to open up billions in hospital Covid-19 grants in coming weeks